YWYang Wang

Yang Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yang Wang has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Bailin Zhang

    Department of Breast Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

    2 shared publications
  • Ding-Yuan Wang

    NCC: National Cancer Center

    1 shared publication
  • Ding-Yuan Wang

    Department of Breast Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

    1 shared publication
  • Ji-Dong Gao

    NCC: National Cancer Center

    1 shared publication
  • Jidong Gao

    Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China

    1 shared publication
  • Ke-Na Bu

    Xingyuan Hospital of Yulin City, Yulin City, China

    1 shared publication

Latest Publications

  • Open Access

    Prognosis prediction and risk stratification of breast cancer patients based on a mitochondria-related gene signature

    by Yang Wang, Ding-Yuan Wang, Ke-Na Bu, Ji-Dong Gao, Bai-Lin Zhang

    As the malignancy with the highest global incidence, breast cancer represents a significant threat to women’s health. Recent advances have shed light on the importance of mitochondrial function in cancer, particularly in metabolic reprogramming within tumors. Recognizing this, we developed a novel risk signature based on mitochondrial-related genes to improve prognosis prediction and risk stratification in breast cancer patients. In this study, transcriptome data and clinical features of breast cancer samples were extracted from two sources: the TCGA, serving as the training set, and the METABRIC, used as the independent validation set. We developed the signature using LASSO-Cox regression and assessed its prognostic efficacy via ROC curves. Furthermore, the signature was integrated with clinical features to create a Nomogram model, whose accuracy was validated through clinical calibration curves and decision curve analysis. To further elucidate prognostic variations between high and low-risk groups, we conducted functional enrichment and immune infiltration analyses. Additionally, the study encompassed a comparison of mutation landscapes and drug sensitivity, providing a comprehensive understanding of the differing characteristics in these groups. Conclusively, we established a risk signature comprising 8 mitochondrial-related genes—ACSL1, ALDH2, MTHFD2, MRPL13, TP53AIP1, SLC1A1, ME3, and BCL2A1. This signature was identified as an independent risk predictor for breast cancer patient survival, exhibiting a significant high hazard ratio (HR = 3.028, 95%CI 2.038–4.499, P < 0.001). Patients in the low-risk group showed a more favorable prognosis, with enhanced immune infiltration, distinct mutation landscapes, and greater sensitivity to anti-tumor drugs. In contrast, the high-risk group exhibited an adverse trend in these aspects. This risk signature represents a novel and effective prognostic indicator, suggesting valuable insights for patient stratification in breast cancer.


  • Open Access

    Prognosis and stratification of breast cancer immune infiltration status based on a mitochondria-related gene signature.

    by Yang Wang, Ding-Yuan Wang, Kena Bu, Bai-Lin Zhang, Ji-Dong Gao

    Background Tumor metabolic reprogramming has attracted extensive attention, and mitochondria play a vital role in this process as a metabolic hub. Despite increasing evidence that mitochondria are involved in breast tumorigenesis, the impact of mitochondria-related genes on breast cancer remains unclear. In this study, we aimed to construct a novel mitochondria-related gene signature through bioinformatic strategies to predict and stratify the prognosis, immune infiltration, and treatment response of breast cancer patients. Methods The transcriptomic data and clinical features of breast cancer samples were extracted from The Cancer Genome Atlas and Molecular Taxonomy of Breast Cancer International Consortium databases. We constructed a mitochondria-related gene signature to predict survival, and Cox regression and receiver operating characteristic were used to evaluate the overall predictive performance. Subsequently, we combined the risk scores with corresponding clinical features to construct a nomogram model and evaluated the model’s accuracy by clinical calibration curve and decision curve analysis. After dividing patients based on risk scores, several immune-related analyses were performed to compare the immune infiltration status between different groups. Finally, we compared the mutation status and drug sensitivity to explore the treatment response and underlying mechanism of the difference in prognosis. Results We constructed an eight mitochondria-related gene risk signature by bioinformatic strategies and verified it by Cox regression, receiver operating characteristic, calibration curve and decision curve analyses. Patients with low-risk score have a better prognosis, enhanced immune infiltration, significantly different mutation landscapes, and a more sensitive response to antitumor drugs, which may account for the favorable survival. Conclusion The mitochondria-related gene signature is a novel prognostic risk signature that can be used as a predictor for patient stratification in breast cancer. In addition, this signature can effectively distinguish the immune infiltration and drug sensitivity status of patients. This may provide a new perspective for the treatment of breast cancer focusing on mitochondria.